Emre Tunçel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emre Tunçel has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Figen Tirnaksiz
Department of Pharmaceutical Technology, Faculty of Pharmacy, Gazi University, Ankara, Türkiye
2 shared publications - Heybet Kerem Polat
Republic of Turkey Ministry of Health, Turkish Medicines And Medical Devices Agency
2 shared publications - Nihat Kurt
Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey
2 shared publications Serdar Tort
2 shared publicationsSevtap Han
2 shared publications- Yasin Turanlı
Republic of Turkey Ministry of Health Turkish Medicines and Medical Devices Agency Ankara Türkiye
2 shared publications
Latest Publications
- Open Access
- 2 August 2026
- Published by Wiley in Journal of the Science of Food and Agriculture
From nature to nanoscale: advances, challenges, and preclinical translation of nanofiber drug delivery systems containing plant‐derived active ingredients
Since the early 1960s, nanotechnology has been a critical area of science, allowing for the development of sophisticated nanomaterials. Nanofibers, one of the most widely used nanotechnological drug delivery systems, have emerged as a highly versatile platform within modern pharmaceutical sciences. By combining various polymers with active herbal ingredients, these systems mimic the natural extracellular matrix and provide improved functions such as a high surface area‐to‐volume ratio, drug targeting, and controlled drug release. Preclinical studies demonstrate that phytochemical‐containing nanofibers have improved therapeutic profiles, including higher anti‐inflammatory, antioxidant, antimicrobial, and antineoplastic effects. In various biomedical applications, such as promoting tissue engineering (such as bone and nerve regeneration), limiting tumor growth, and accelerating wound closure, it was shown that nanofibers may overcome the physicochemical limitations of herbal drugs such as low solubility and bioavailability. Despite promising preclinical study results, there are significant obstacles in the way of the commercialization of herbal drug‐loaded nanofibers. The difficult standardization of multi‐component herbal extracts, stabilization drawbacks, and the absence of scalable industrial manufacturing equipment that can maintain repeatable characterization of nanofibers are some of the major obstacles, in addition to a lack of clinical trials. To navigate the clinical translation of nanofibers, interdisciplinary collaboration regarding quality control, safety, and regulatory pathways is strictly necessary due to the case‐by‐case review approach utilized by regulatory bodies such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). This review offers a comprehensive overview of research on herbal drug‐loaded nanofibers and contributes a novel perspective with regulatory and clinical translational insights. © 2026 The Author(s). Journal of the Science of Food and Agriculture published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
- 2 August 2026
- Published by Wiley in Journal of the Science of Food and Agriculture
Open AccessFrom nature to nanoscale: advances, challenges, and preclinical translation of nanofiber drug delivery systems containing plant‐derived active ingredients
Since the early 1960s, nanotechnology has been a critical area of science, allowing for the development of sophisticated nanomaterials. Nanofibers, one of the most widely used nanotechnological drug delivery systems, have emerged as a highly versatile platform within modern pharmaceutical sciences. By combining various polymers with active herbal ingredients, these systems mimic the natural extracellular matrix and provide improved functions such as a high surface area‐to‐volume ratio, drug targeting, and controlled drug release. Preclinical studies demonstrate that phytochemical‐containing nanofibers have improved therapeutic profiles, including higher anti‐inflammatory, antioxidant, antimicrobial, and antineoplastic effects. In various biomedical applications, such as promoting tissue engineering (such as bone and nerve regeneration), limiting tumor growth, and accelerating wound closure, it was shown that nanofibers may overcome the physicochemical limitations of herbal drugs such as low solubility and bioavailability. Despite promising preclinical study results, there are significant obstacles in the way of the commercialization of herbal drug‐loaded nanofibers. The difficult standardization of multi‐component herbal extracts, stabilization drawbacks, and the absence of scalable industrial manufacturing equipment that can maintain repeatable characterization of nanofibers are some of the major obstacles, in addition to a lack of clinical trials. To navigate the clinical translation of nanofibers, interdisciplinary collaboration regarding quality control, safety, and regulatory pathways is strictly necessary due to the case‐by‐case review approach utilized by regulatory bodies such as the US Food and Drug Administration (FDA) and European Medicines Agency (EMA). This review offers a comprehensive overview of research on herbal drug‐loaded nanofibers and contributes a novel perspective with regulatory and clinical translational insights. © 2026 The Author(s). Journal of the Science of Food and Agriculture published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
- 29 April 2026
- Published by Springer Nature in Bulletin of Materials Science
- Vol. 49 (2)
Silk-based drug delivery systems: Advances, challenges, and future perspectives
- 29 April 2026
- Published by Springer Nature in Bulletin of Materials Science
- Vol. 49 (2)
Silk-based drug delivery systems: Advances, challenges, and future perspectives
- 17 September 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (12) , 103995
Development and characterization of ivermectin loaded microneedle formulations using 3D printed molds
- 17 September 2025
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 114 (12) , 103995
Development and characterization of ivermectin loaded microneedle formulations using 3D printed molds
- 25 October 2024
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 15 (6) , 2116-2145
Development and optimization of hydrogel-forming microneedles fabricated with 3d-printed molds for enhanced dermal diclofenac sodium delivery: a comprehensive in vitro, ex vivo, and in vivo study
With the developing manufacturing technologies, the use of 3D printers in microneedle production is becoming widespread. Hydrogel-forming microneedles (HFMs), a variant of microneedles, demonstrate distinctive features such as a high loading capacity and controlled drug release. In this study, the conical microneedle master molds with approximately 500 μm needle height and 250 μm base diameter were created using a Stereolithography (SLA) 3D printer and were utilized to fabricate composite HFMs containing diclofenac sodium. Using Box–Behnken Design, the effects of different polymers on swelling index and mechanical strength of the developed HFMs were evaluated. The optimum HFMs were selected according to experimental design results with the aim of the highest mechanical strength with varying swelling indexes, which was needed to use 20% Gantrez S97 and 0.1% (F22), 0.42% (F23), and 1% (F24) hyaluronic acid. The skin penetration and drug release properties of the optimum formulations were assessed. Ex vivo studies were conducted on formulations to determine drug penetration and accumulation. F24, which has the highest mechanical strength and optimized swelling index, achieved the highest drug accumulation in the skin tissue (17.70 ± 3.66%). All optimum HFMs were found to be non-cytotoxic by the MTT cell viability test (> 70% cell viability). In in vivo studies, the efficacy of the F24 was assessed for the treatment of xylene-induced ear edema by contrasting it to the conventional dosage form. It was revealed that HFMs might be an improved replacement for conventional dosage forms in terms of dermal diseases such as actinic keratosis. Graphical Abstract
- 25 October 2024
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 15 (6) , 2116-2145
Development and optimization of hydrogel-forming microneedles fabricated with 3d-printed molds for enhanced dermal diclofenac sodium delivery: a comprehensive in vitro, ex vivo, and in vivo study
With the developing manufacturing technologies, the use of 3D printers in microneedle production is becoming widespread. Hydrogel-forming microneedles (HFMs), a variant of microneedles, demonstrate distinctive features such as a high loading capacity and controlled drug release. In this study, the conical microneedle master molds with approximately 500 μm needle height and 250 μm base diameter were created using a Stereolithography (SLA) 3D printer and were utilized to fabricate composite HFMs containing diclofenac sodium. Using Box–Behnken Design, the effects of different polymers on swelling index and mechanical strength of the developed HFMs were evaluated. The optimum HFMs were selected according to experimental design results with the aim of the highest mechanical strength with varying swelling indexes, which was needed to use 20% Gantrez S97 and 0.1% (F22), 0.42% (F23), and 1% (F24) hyaluronic acid. The skin penetration and drug release properties of the optimum formulations were assessed. Ex vivo studies were conducted on formulations to determine drug penetration and accumulation. F24, which has the highest mechanical strength and optimized swelling index, achieved the highest drug accumulation in the skin tissue (17.70 ± 3.66%). All optimum HFMs were found to be non-cytotoxic by the MTT cell viability test (> 70% cell viability). In in vivo studies, the efficacy of the F24 was assessed for the treatment of xylene-induced ear edema by contrasting it to the conventional dosage form. It was revealed that HFMs might be an improved replacement for conventional dosage forms in terms of dermal diseases such as actinic keratosis. Graphical Abstract
- Open Access
- 2 July 2024
- Published by Springer Nature in Research Square
Development and In Vitro - In Vivo Evaluation of Composite Hydrogel-Forming Microneedles Containing Diclofenac Sodium with Box-Behnken Design Using SLA 3D-Printed Microneedle Molds
With developing manufacturing technologies, the use of 3D printers in microneedle production is becoming widespread. In recent years, microneedles have gained considerable popularity as dermal drug delivery systems. Hydrogel-forming microneedles (HFMs), a variant of microneedles, demonstrate distinctive features such as a high loading capacity, controlled drug release, and enhanced drug absorption. In this study, the molds, created using a Stereolithography (SLA) 3D printer, were utilized to create composite HFMs containing diclofenac sodium. Using an experimental design approach (Box–Behnken Design), the effects of different polymers on the in vitro performance of the developed HFMs, as well as the impact of polymer mixtures on microneedle formation were investigated. The skin penetration and drug release properties of the proposed formulations were assessed. Ex vivo studies were conducted on formulations to determine drug penetration and accumulation in tissue, and the MTT testing revealed non-cytotoxicity. Subsequently, in in vivo studies, the efficacy of the optimal formulation was assessed for the treatment of xylene-induced ear edema by contrasting it to the conventional dosage form. As a result, it was observed that HFMs could provide high amounts of drug accumulation in the skin tissue.
- 2 July 2024
- Published by Springer Nature in Research Square
Open AccessDevelopment and In Vitro - In Vivo Evaluation of Composite Hydrogel-Forming Microneedles Containing Diclofenac Sodium with Box-Behnken Design Using SLA 3D-Printed Microneedle Molds
With developing manufacturing technologies, the use of 3D printers in microneedle production is becoming widespread. In recent years, microneedles have gained considerable popularity as dermal drug delivery systems. Hydrogel-forming microneedles (HFMs), a variant of microneedles, demonstrate distinctive features such as a high loading capacity, controlled drug release, and enhanced drug absorption. In this study, the molds, created using a Stereolithography (SLA) 3D printer, were utilized to create composite HFMs containing diclofenac sodium. Using an experimental design approach (Box–Behnken Design), the effects of different polymers on the in vitro performance of the developed HFMs, as well as the impact of polymer mixtures on microneedle formation were investigated. The skin penetration and drug release properties of the proposed formulations were assessed. Ex vivo studies were conducted on formulations to determine drug penetration and accumulation in tissue, and the MTT testing revealed non-cytotoxicity. Subsequently, in in vivo studies, the efficacy of the optimal formulation was assessed for the treatment of xylene-induced ear edema by contrasting it to the conventional dosage form. As a result, it was observed that HFMs could provide high amounts of drug accumulation in the skin tissue.